An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases
Journal
European journal of nuclear medicine and molecular imaging
Date Issued
2021-02-22
Author(s)
Husseini, Jad S
Amorim, Bárbara Juarez
Torrado-Carvajal, Angel
Prabhu, Vinay
Groshar, David
Umutlu, Lale
Herrmann, Ken
Cañamaque, Lina García
Garzón, José Ramón García
Palmer, William E
Heidari, Pedram
Sosna, Jacob
Matushita, Cristina
Cerci, Juliano
Queiroz, Marcelo
Muglia, Valdair Francisco
Nogueira-Barbosa, Marcello H
Borra, Ronald J H
Kwee, Thomas C
Glaudemans, Andor W J M
Evangelista, Laura
Salvatore, Marco
Cuocolo, Alberto
Soricelli, Andrea
Herold, Christian
Laghi, Andrea
Mayerhoefer, Marius
Mahmood, Umar
Catana, Ciprian
Daldrup-Link, Heike E
Rosen, Bruce
Catalano, Onofrio A
Abstract
MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use.
Subjects
MR; Metastases; Osseous; PET; PET/MR; PET/MRI; Skeletal
SDGs
Other Subjects
dotanoc ga 68; edotreotide ga 68; fluciclovine f 18; fluorodeoxyglucose f 18; gallium dotatate ga 68; prostate specific membrane antigen f 18; prostate specific membrane antigen ga 68; sodium fluoride f 18; tracer; unclassified drug; radiopharmaceutical agent; adult; Article; bone metastasis; breast cancer; cancer diagnosis; cancer staging; consensus; diagnostic value; human; lung cancer; lymphoma; neuroendocrine tumor; nuclear magnetic resonance imaging; positron emission tomography; positron emission tomography-computed tomography; primary tumor; prostate adenocarcinoma; radiation dose; well differentiated neuroendocrine tumor; expert witness; nuclear magnetic resonance imaging; positron emission tomography; positron emission tomography-computed tomography; Expert Testimony; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals
Type
journal article